The Pursuit of Clinically Relevant Measures of Platelet Function After Antiplatelet Drug Therapy

Journal of the American College of Cardiology

Volumn 52, Issue 24, 2008, Pages 1978-1980

  Cairns, John A ^a   Eikelboom, John ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

antiplatelet drugs; clopidogrel; clopidogrel resistance; platelet function tests

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DRUG METABOLITE; PRASUGREL; TICAGRELOR; VASODILATOR STIMULATED PHOSPHOPROTEIN; WARFARIN;

AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG RESPONSE; EDITORIAL; HUMAN; LOADING DRUG DOSE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT FAILURE;

BLOOD PLATELETS; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; HUMANS; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RISK FACTORS; THIOPHENES; TICLOPIDINE; TREATMENT FAILURE;

EID: 56849091045     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.08.053     Document Type: Editorial

References (19)

1. Patrono C., Baigent C., Hirsh J., and Roth G. Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133 (2008) 199S-233S
2. Gurbel P.A., Becker R.C., Mann K.G., Steinhubl S.R., and Michelson A.D. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 50 (2007) 1822-1834
3. Cairns J.A., and Eikelboom J.W. Clopidogrel resistance: more grist for the mill. J Am Coll Cardiol 51 (2008) 1936-1938
4. Frere C., Cuisset T., Quilici J., et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 98 (2007) 838-843
5. Bonello L., Paganelli F., Arpin-Bornet M., et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 5 (2007) 1630-1636
6. Bliden K.P., DiChiara J., Tantry U.S., Bassi A.K., Chaganti S.K., and Gurgel P.A. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?. J Am Coll Cardiol 49 (2007) 657-666
7. Hochholzer W., Trenk D., Bestehorn H.P., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48 (2006) 1742-1750
8. Lev E.I., Patel R.T., Maresh K.J., et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous intervention: the role of dual drug resistance. J Am Coll Cardiol 47 (2006) 27-33
9. Geiger J., Teichmann L., Grossmann R., et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem 51 (2005) 957-965
10. Aleil B., Ravanat C., Cazanave P., Rochoux G., Heitz A., and Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 3 (2005) 85-92
11. Harrison P., Frelinger A.L., Furman M.I., and Michelson A.D. Measuring antiplatelet drug effects in the laboratory. Thromb Res 120 (2007) 323-336
12. 12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 29 (2008) 21-30
13. Erlinge D., Varenhorst C., Braun O.Ö., et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 52 (2008) 1968-1977
14. Guyatt C. Determining prognosis and creating clinical decision rules. In: Haynes B., Sackett D., Guyatt G., and Tugwell P. (Eds). Clinical Epidemiology. How to Do Clinical Practice Research (2006), Lippincott Williams and Wilkins, Philadelphia, PA
15. GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety. http://www.clinicaltrials.gov/ct2/show/NCT00645918?term=NCT00645918& rank=1 Accessed October 10, 2008
16. Wiviott S.D., Trenk D., Frelinger A.L., et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis In Myocardial Infarction 44 trial. Circulation 116 (2007) 2923-2932
17. O'Donoghue M., and Wiviott S.D. Clopidogrel response variability and future therapies: does one size fit all?. Circulation 114 (2006) e600-e606
18. Angiolillo D.J., Bernardo E., Sabate M., et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 50 (2007) 1541-1547
19. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). J Am Coll Cardiol 50 (2007) e1-e157